Myasthenia gravis is a neuromuscular disorder that affects striated muscles especially those innervated by the cranial nerves. The standard diagnostic regimen is to find a reversal of symptoms by acetylcholine esterase administration. The permanent and objective recording of this effect is the key to an accurate assessment of this test. The voice spectrograph is a noninvasive means of evaluating the voice. It has been used successfully to mate a clear and specific diagnosis of myasthenia gravis as it affects the larynx. The test can be used to distinguish myasthenia gravis from other functional, anatomical and neuromuscular laryngeal disorders.
Get full access to this article
View all access options for this article.
References
1.
AronsonER: Early motor unit disease masquerading as psychogenic breathy dysphonia. J Speech Hear Disord36: 115–124, 1971.
2.
HorowitzSH: Electrophysiologic diagnosis of myasthenia gravis and the regional curare test. Neurology26: 410–417, 1976.
3.
DrachmanDB: Myasthenia gravis. New Engl J Med298: 136–142, 186–193, 1978.
4.
GrobD: Myasthenia gravis current status of pathogenesis, clinical manifestations and management. J Chronic Dis8: 536–566, 1958.
5.
StuartWD: Otolaryngologic aspects of myasthenia gravis. Laryngoscope75: 112–121, 1965.
6.
MaxwellSLockeJL: Voice in myasthenia gravis. Laryngoscope79: 1902–1906, 1969.
7.
NeimanRFMountjoyJRAllenEL: Myasthenia gravis focal to the larynx. Arch Otolaryngol101: 569–570, 1975.
8.
RontalERontalMRolnickM: Use of voice spectrography in the clinical evaluation of vocal cord injection. Laryngoscope85: 47–56, 1975.
9.
RontalERontalMRolnickM: Objective evaluation of vocal pathology using voice spectrography. Ann Otol Rhinol Laryngol84: 662–672, 1972.
